STOCK TITAN

Schrodinger, Inc. SEC Filings

SDGR NASDAQ

Welcome to our dedicated page for Schrodinger SEC filings (Ticker: SDGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing Schrodinger’s regulatory paperwork can feel like running a quantum simulation of its own. Each filing blends enterprise-software metrics with early-stage drug-discovery data, making it hard to spot recurring license revenue, milestone payments, or cash-burn trends in a 300-page 10-K. Stock Titan’s AI turns that complexity into clarity, so you can locate pipeline updates or collaboration accounting in seconds instead of hours.

Need the numbers from the latest Schrodinger quarterly earnings report 10-Q filing? Curious about option exercises inside Schrodinger insider trading Form 4 transactions? Our platform flags every new document the moment it hits EDGAR and delivers plain-English explanations that answer the questions analysts actually ask—“How did deferred revenue change?”, “Which segments drove margin shifts?”, or “What triggers the next milestone payment?”

Here’s how professionals use the page:

  • Track Schrodinger executive stock transactions Form 4 in real time and gauge insider sentiment.
  • Dive into segment footnotes with an AI summary that makes Schrodinger annual report 10-K simplified.
  • Receive instant alerts when a surprise Schrodinger 8-K material events explained filing outlines new collaborations or financing.
  • Compare R&D spend across quarters with our Schrodinger earnings report filing analysis.
  • Review governance details in the Schrodinger proxy statement executive compensation section without scrolling through appendices.

Whether you’re understanding Schrodinger SEC documents with AI for valuation models or monitoring Schrodinger Form 4 insider transactions real-time before material announcements, Stock Titan provides the complete, continually updated filing set plus the context you need to act confidently.

Rhea-AI Summary

Schrodinger Director Jeffrey Chodakewitz reported two significant equity transactions on June 18, 2025:

  • Received 5,997 Restricted Stock Units (RSUs) at $0, bringing total beneficial ownership to 17,247 shares. RSUs vest after 12 months or by next annual stockholder meeting, with settlement deferred until separation from service or change in control.
  • Granted stock options to purchase 9,341 shares at an exercise price of $21.05 per share, expiring June 18, 2035. Options follow the same vesting schedule as RSUs.

Both awards were granted under the company's 2022 Equity Incentive Plan. The transactions represent standard board of director compensation, with vesting contingent on continued service. The Form 4 was filed by Donald Shum as attorney-in-fact on June 20, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Schrodinger Director Gary Sender reported significant equity compensation transactions on June 18, 2025. The insider received two key awards:

  • 5,997 Restricted Stock Units (RSUs) granted under the 2022 Equity Incentive Plan, bringing total beneficial ownership to 17,247 shares. These RSUs vest after 12 months or by the next annual stockholder meeting, whichever comes first.
  • Stock Options to purchase 9,341 shares at an exercise price of $21.05 per share. These options expire on June 18, 2035 and follow the same vesting schedule as the RSUs.

Both awards are subject to continued service requirements and were granted as part of the company's director compensation program. The transactions were reported via Form 4 filing, with Donald Shum signing as attorney-in-fact for Gary Sender on June 20, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Schrodinger Director Michael Lynton reported significant equity compensation grants on June 18, 2025, consisting of two main components:

  • 5,997 Restricted Stock Units (RSUs) granted under the 2022 Equity Incentive Plan, bringing total beneficial ownership to 17,247 shares. These RSUs vest after 12 months or by the next annual stockholder meeting, with deferred settlement until 30 days after separation or change in control.
  • 9,341 Stock Options with a $21.05 exercise price, expiring June 18, 2035. The options follow the same vesting schedule as the RSUs - one year or next annual meeting, subject to continued service.

The Form 4 filing, executed by Donald Shum as attorney-in-fact on June 20, 2025, reflects standard director compensation practices and aligns the director's interests with shareholders through equity-based awards. All securities are held directly with no indirect ownership reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Schrodinger Director Receives Equity Compensation

Director Bridget van Kralingen received new equity awards from Schrodinger (SDGR) on June 18, 2025, consisting of:

  • 1,499 Restricted Stock Units (RSUs) with a $0 exercise price, bringing total RSU holdings to 11,499 units
  • 2,335 Stock Options with an exercise price of $21.05, expiring June 18, 2035

Both awards vest on the earlier of (1) the twelve-month anniversary of the grant date or (2) the next annual stockholder meeting, subject to continued service. RSU settlement is deferred until 30 days after separation from service or a change in control event. The grants were made under the company's 2022 Equity Incentive Plan. This filing represents standard board of director compensation rather than open market transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Schrodinger (SDGR) director Nancy Thornberry reported two significant equity compensation grants on June 18, 2025:

  • 5,997 Restricted Stock Units (RSUs) granted under the 2022 Equity Incentive Plan, bringing total beneficial ownership to 17,247 shares. RSUs vest after 12 months or by the next annual stockholder meeting, with settlement deferred until separation from service or change in control.
  • 9,341 Stock Options with a $21.05 exercise price, expiring June 18, 2035. Options follow the same vesting schedule as the RSUs.

These grants represent standard director compensation aligned with the company's equity incentive plan. The transaction was executed directly, with no indirect ownership reported. All securities were acquired at $0 cost as part of director compensation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Schrodinger Director Rosana Kapeller-Libermann received significant equity compensation on June 18, 2025, consisting of two components:

  • 5,997 Restricted Stock Units (RSUs) granted under the 2022 Equity Incentive Plan, bringing total beneficial ownership to 17,247 shares. RSUs vest after 12 months or by next annual meeting, with settlement deferred until separation or change in control
  • 9,341 Stock Options with exercise price of $21.05, expiring June 18, 2035. Options follow same vesting schedule as RSUs

This Form 4 filing reflects standard director compensation practices, with a mix of RSUs and options designed to align the director's interests with shareholders. The vesting structure encourages retention while the RSU deferral mechanism promotes long-term alignment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

On 18 June 2025, Schrödinger, Inc. (SDGR) filed a Form 4 reporting routine director compensation for board member Gary L. Ginsberg. The award package comprises:

  • 5,997 restricted stock units (RSUs) granted at no cost; each RSU converts into one common share when settled.
  • Stock options for 9,341 shares with a $21.05 exercise price.

Both the RSUs and the options vest on the earlier of (i) the 12-month anniversary of the 18 Jun 2025 grant date or (ii) the next annual shareholder meeting, subject to Ginsberg’s continued board service. Settlement of vested RSUs is deferred until the earlier of (a) 30 days after separation from service or (b) specific change-in-control events.

Following the grant, Ginsberg’s direct beneficial ownership rises to 17,247 common shares (including the newly issued 5,997 unvested RSUs) plus the newly granted option rights. No shares were sold or disposed of, and all transactions were executed at $0 cash cost to the company or insider.

The filing, signed 20 Jun 2025, reflects normal annual director equity awards under the company’s 2022 Equity Incentive Plan and is not expected to have a material impact on Schrödinger’s capital structure or near-term financials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Schrödinger, Inc. (SDGR) – Form 4 insider filing dated 20-Jun-2025

Director Arun Oberoi reported two equity awards granted on 18-Jun-2025 under the company’s 2022 Equity Incentive Plan:

  • 5,997 Restricted Stock Units (RSUs) (Transaction code “A”, price $0). All RSUs vest on the earlier of 12-month anniversary or the next annual shareholder meeting, subject to continued service.
  • 9,341 stock options with an exercise price of $21.05, expiring 18-Jun-2035. The option vesting schedule mirrors the RSUs.

After the grant, Oberoi’s direct beneficial ownership increases to 17,247 common shares, which includes the 5,997 unvested RSUs. No shares were sold or disposed of; the filing reflects a routine, non-cash compensation grant intended to align director incentives with shareholder interests. The incremental dilution is de-minimis in the context of Schrödinger’s total share count and is unlikely to materially affect valuation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Schrodinger, Inc. (SDGR) – Form 4 insider filing dated 20 June 2025

Director Dr. Richard Friesner reported routine equity awards granted on 18 June 2025 under the company’s 2022 Equity Incentive Plan.

  • Restricted stock units (RSUs): 5,997 units awarded at no cost. Each RSU converts into one common share. Vesting occurs on the twelve-month anniversary of grant or the date of the next annual shareholders’ meeting, whichever comes first. Settlement is deferred until the earlier of 30 days after the director leaves the company or a qualifying change-of-control event.
  • Stock options: right to purchase 9,341 common shares at an exercise price of $21.05. The options share the same vesting trigger and carry a 10-year term, expiring 18 June 2035.

Post-transaction ownership

  • Direct: 521,697 shares (includes the 5,997 unvested RSUs)
  • Indirect: 694,925 shares held by a 2018 Grantor Retained Annuity Trust and 28,328 shares held by the director’s spouse
  • Total beneficial ownership: ≈1.245 million shares

Implications for investors: The filing shows no dispositions; all reported codes are “A” (acquisitions), indicating incentive alignment rather than open-market sentiment. The size of the award is immaterial relative to SDGR’s total shares outstanding and therefore unlikely to move the stock on its own. Nevertheless, continued significant insider ownership can be viewed as a governance positive.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Schrodinger (SDGR)?

The current stock price of Schrodinger (SDGR) is $20.61 as of June 28, 2025.

What is the market cap of Schrodinger (SDGR)?

The market cap of Schrodinger (SDGR) is approximately 1.5B.

What is Schrodinger, Inc.'s core business model?

Schrodinger, Inc. operates through two primary segments: a Software segment that provides advanced molecular simulation tools, and a Drug Discovery segment that leverages strategic research collaborations. These activities support innovation in pharmaceutical and material science research.

How does Schrodinger generate revenue?

The company generates revenue from the sales of its enterprise software solutions and from research funding along with milestone payments through collaborations in drug discovery. This dual approach reflects its integrated business model.

Which industries benefit from Schrodinger's solutions?

Schrodinger serves a variety of industries including pharmaceuticals, biotechnology, and materials science. Its molecular simulation software is pivotal in accelerating research in life sciences and support fields such as chemical and electronics research.

What distinguishes Schrodinger's simulation software?

Its software is recognized for its advanced computational capabilities that deliver predictive insights to facilitate faster and more precise research. The technology not only supports cost reduction but also fosters breakthrough discoveries in drug development.

What role do collaborations play in Schrodinger's business?

Collaborations are central to Schrodinger’s approach; the company engages with leading pharmaceutical and biotechnology firms to drive innovative drug discovery programs. These partnerships enhance the application and trust in its software solutions.

How is scientific expertise reflected in the company's operations?

Schrodinger has consistently invested in basic research, resulting in a strong portfolio of peer-reviewed scientific publications. This rigorous approach underpins the credibility of its simulation software and the reliability of its research collaborations.

How does Schrodinger compare to competitors in its field?

By integrating advanced molecular simulations with active drug discovery programs, Schrodinger offers a more holistic solution compared to companies that focus solely on software or research alone. Its combination of technological innovation and scientific validation sets it apart in a competitive market.
Schrodinger, Inc.

NASDAQ:SDGR

SDGR Rankings

SDGR Stock Data

1.49B
62.51M
2.49%
97.93%
12.67%
Health Information Services
Pharmaceutical Preparations
Link
United States
NEW YORK